Zilovertamab vedotin
Product Specifications
UNSPSC Description
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer[1].
Target Antigen
Antibody-Drug Conjugates (ADCs); Apoptosis
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related;Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zilovertamab-vedotin.html
Purity
98.15
Solubility
10 mM in DMSO
Smiles
[Zilovertamab vedotin]
Molecular Weight
151000 (average)
References & Citations
[1]Jiang VC, et, al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021 Aug 28;14(1):132.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99956/Zilovertamab-vedotin-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99956/Zilovertamab-vedotin-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
